Bacteriophage Qβ virus-like particles displaying Chikungunya virus B-cell epitopes elicit high-titer E2 protein antibodies but fail to neutralize a Thailand strain of Chikungunya virus

Basu, Rupsa; Zhai, Lukai; Rosso, Brenna; Tumban, Ebenezer

doi:10.1016/j.vaccine.2020.01.091

Cited by 9 publications

(9 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When tested in a mouse model, immunized mice were not protected from Zika challenge, but serum antibodies from immunized mice neutralized the virus in vitro , indicating that this approach has potential for vaccine development. A similar strategy was also used to conjugate Qβ VLPs to CHIKV epitopes ( Basu et al, 2020 ) and Dengue virus (DENV) epitopes ( Warner and Frietze, 2021 ), as well as to conjugate CMV VLPs to recombinant SARS-CoV-2 spike protein ( Zha et al, 2021 ) and ZIKV immunogens ( Cabral-Miranda et al, 2019 ). Other linkers used for conjugation of VLP platforms to pathogenic antigens include SM(PEG) 4 (N-hydroxysuccinimide-poly (ethylene glycol) 4 -maleimide) ( Ortega-Rivera et al, 2021 ) for conjugation of Qβ to SARS-CoV-2 spike protein, and carbodiimide chemistry for conjugation of Yersenia pestis virulence factors ( Arnaboldi et al, 2016 ) to TMV VLPs.…”

Section: Virus-like Particlesmentioning

confidence: 99%

Biological Nanoparticles in Vaccine Development

Curley

Putnam

2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Vaccines represent one of the most successful public health initiatives worldwide. However, despite the vast number of highly effective vaccines, some infectious diseases still do not have vaccines available. New technologies are needed to fully realize the potential of vaccine development for both emerging infectious diseases and diseases for which there are currently no vaccines available. As can be seen by the success of the COVID-19 mRNA vaccines, nanoscale platforms are promising delivery vectors for effective and safe vaccines. Synthetic nanoscale platforms, including liposomes and inorganic nanoparticles and microparticles, have many advantages in the vaccine market, but often require multiple doses and addition of artificial adjuvants, such as aluminum hydroxide. Biologically derived nanoparticles, on the other hand, contain native pathogen-associated molecular patterns (PAMPs), which can reduce the need for artificial adjuvants. Biological nanoparticles can be engineered to have many additional useful properties, including biodegradability, biocompatibility, and are often able to self-assemble, thereby allowing simple scale-up from benchtop to large-scale manufacturing. This review summarizes the state of the art in biologically derived nanoparticles and their capabilities as novel vaccine platforms.

show abstract

Section: Virus-like Particlesmentioning

confidence: 99%

Biological Nanoparticles in Vaccine Development

Curley

Putnam

2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…Yeastderived VLPs showed efficient in vitro and in vivo neutralization activity and conferred protection in CHIKV infected neonatal mice (198). Bacteriophage VLPs displaying immunogenic peptides represent an alternative approach; a recent publication showed that E2 derived B cell epitopes displayed in such a manner can induce neutralizing antibodies (199).…”

Section: Virus-like Particle Vaccinesmentioning

confidence: 99%

Current Efforts in the Development of Vaccines for the Prevention of Zika and Chikungunya Virus Infections

et al. 2020

View full text Add to dashboard Cite

Arboviruses represent major challenges to public health, particularly in tropical, and subtropical regions, and a substantial risk to other parts of the world as respective vectors extend their habitats. In recent years, two viruses transmitted by Aedes mosquitoes, Chikungunya and Zika virus, have gathered increased interest. After decades of regionally constrained outbreaks, both viruses have recently caused explosive outbreaks on an unprecedented scale, causing immense suffering and massive economic burdens in affected regions. Chikungunya virus causes an acute febrile illness that often transitions into a chronic manifestation characterized by debilitating arthralgia and/or arthritis in a substantial subset of infected individuals. Zika infection frequently presents as a mild influenza-like illness, often subclinical, but can cause severe complications such as congenital malformations in pregnancy and neurological disorders, including Guillain-Barré syndrome. With no specific treatments or vaccines available, vector control remains the most effective measure to manage spread of these diseases. Given that both viruses cause antibody responses that confer long-term, possibly lifelong protection and that such responses are cross-protective against the various circulating genetic lineages, the development of Zika and Chikungunya vaccines represents a promising route for disease control. In this review we provide a brief overview on Zika and Chikungunya viruses, the etiology and epidemiology of the illnesses they cause and the host immune response against them, before summarizing past and current efforts to develop vaccines to alleviate the burden caused by these emerging diseases. The development of the urgently needed vaccines is hampered by several factors including the unpredictable epidemiology, feasibility of rapid clinical trial implementation during outbreaks and regulatory pathways. We will give an overview of the current developments.

show abstract

“…There are currently a significant number of research groups developing VLP-based vaccines against several viruses including the following: human cytomegalovirus, influenza, ,,, chikungunya, ,,− zika, dengue, duck tembusu, bluetongue, foot-and-mouth disease, , HIV-1, poliovirus, porcine circovirus type 2, human papilloma, and respiratory syncytial and zaire ebolavirus viruses. For example, influenza virus-based VLPs containing several Toxoplasma gondii proteins (IMC, ROP18, and MIC8) were assembled by coexpression with the M protein from the influenza virus.…”

Section: Vaccinesmentioning

confidence: 99%

“…For example, Qβ particles have been applied in the development of several vaccine candidates based on VLPs chemically decorated with specific peptides. This is the case of a CHIKV vaccine prototype in which B-cell epitopes were attached to the VLP, 24 which were able to elicit high titers of anti-E2 protein antibodies. Unfortunately, this system failed to neutralize the virus.…”

Section: Vaccinesmentioning

confidence: 99%

“…The generation of virus-like particles (VLPs) was first described in 1955 with the in vitro reconstitution of the tobacco mosaic virus (TMV) . Since then, VLPs became key entities to study the physical properties and interactions that control virus assembly, which has set the basis for the development of bionanomaterials, , cargo/drug delivery systems, − nanoreactors, − gene therapy vehicles, − selective carriers for contrast media, − diagnostics, and vaccines. − The development of different types of VLPs has allowed us to understand the rules of capsid assembly and genome packaging and to apply them in the rational design of self-replicating VLPs and/or nanomaterials that have functions that can be tailored to specific needs. The advent of genetic engineering and the advances in structural virology led to significant progress in the implementation of systems for the design and production of VLPs.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Role of Virus-Like Particles in Medical Biotechnology

2020

View full text Add to dashboard Cite

Virus-like particles (VLPs) are protein-based, nanoscale, self-assembling, cage architectures, which have relevant applications in biomedicine. They can be used for the development of vaccines, imaging approaches, drug and gene therapy delivery systems, and in vitro diagnostic methods. Today, three relevant viruses are targeted using VLP-based recombinant vaccines. VLPbased drug delivery, nanoreactors for therapy, and imaging systems are approaches under development with promising outcomes. Several VLP-based vaccines are under clinical evaluation. Herein, an updated view on the VLP-based biomedical applications is provided; advanced methods for the production, functionalization, and drug loading of VLPs are described, and perspectives for the field are identified.

show abstract

Bacteriophage Qβ virus-like particles displaying Chikungunya virus B-cell epitopes elicit high-titer E2 protein antibodies but fail to neutralize a Thailand strain of Chikungunya virus

Cited by 9 publications

References 43 publications

Biological Nanoparticles in Vaccine Development

Biological Nanoparticles in Vaccine Development

Current Efforts in the Development of Vaccines for the Prevention of Zika and Chikungunya Virus Infections

The Role of Virus-Like Particles in Medical Biotechnology

Contact Info

Product

Resources

About